Last reviewed · How we verify
Artemisia vulgaris — Competitive Intelligence Brief
marketed
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Artemisia vulgaris (Artemisia vulgaris) — Laboratorios Leti, S.L.. Artemisia vulgaris is a herbal preparation that may exert anti-inflammatory and immunomodulatory effects through its volatile oils and sesquiterpene lactones.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Artemisia vulgaris TARGET | Artemisia vulgaris | Laboratorios Leti, S.L. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Artemisia vulgaris CI watch — RSS
- Artemisia vulgaris CI watch — Atom
- Artemisia vulgaris CI watch — JSON
- Artemisia vulgaris alone — RSS
Cite this brief
Drug Landscape (2026). Artemisia vulgaris — Competitive Intelligence Brief. https://druglandscape.com/ci/artemisia-vulgaris. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab